Shedding Light on How Tumors Become Resistant to Immunotherapy

News   Jul 26, 2017 | Original story from University of Zurich

 
Shedding Light on How Tumors Become Resistant to Immunotherapy

The epigenetic control protein Ezh2 plays a central role in how cancer cells develop resistance. (Bild: D. Zingg, UZH)

 
 
 

RELATED ARTICLES

Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment

News

The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.

READ MORE

Cancer Cells Prevent Immune Cells from Producing Cancer Killing Chemicals

News

Researchers have identified a substance released by pancreatic cancer cells that protects them from attack by immune cells called macrophages

READ MORE

Diabetes Drug Could Be Re-purposed to Help End Transplant Rejection

News

A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE